Oculis Holding

OCS

Market cap $672M

British outsourcer Mitie ‌has agreed to be acquired by rival OCS Group ​International for a ​total value of £3.1 billion ($4.17 billion), ⁠the companies said ​on Tuesday.

ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.